Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
investigation
CRO
Icon reveals accounting investigation, withdraws 2025 guidance
The Irish CRO may have overestimated its 2023 and 2024 revenues by less than 2%, according to the company's initial take on the situation.
Darren Incorvaia
Feb 12, 2026 11:12am
Federal watchdog to probe FDA’s handling of major device recalls
Jan 17, 2024 10:24am
Cassava hints 'short-sellers' to blame for leaking CUNY report
Oct 13, 2023 9:46am
Inside the big business of clogged arteries: ProPublica report
Feb 17, 2023 10:30am
Cochlear's Oticon buy faces in-depth antitrust probe in UK
Dec 20, 2022 1:21pm
Philips faces French criminal probe over ventilator recall
Sep 8, 2022 10:29am
